UCB SA
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$178.5M
Doctors Paid
558
Transactions
16,078
2024 Total
$20.6M
Payment Breakdown by Category
Research$170.3M (95.4%)
Consulting$6.7M (3.8%)
Travel$1.2M (0.6%)
Food & Beverage$79,684 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $170.3M | 11,203 | 95.4% |
| Consulting Fee | $6.7M | 1,664 | 3.8% |
| Travel and Lodging | $1.2M | 1,476 | 0.6% |
| Honoraria | $97,749 | 10 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83,913 | 17 | 0.0% |
| Food and Beverage | $79,684 | 1,702 | 0.0% |
| Education | $4,629 | 6 | 0.0% |
Payments by Type
Research
$170.3M
11,203 transactions
General
$8.1M
4,875 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | $12.6M | 1 | 669 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. | $8.5M | 2 | 433 |
| A MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | $8.3M | 3 | 807 |
| A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa | $6.9M | 1 | 573 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAINTENANCE TREATMENT PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | $5.7M | 0 | 90 |
| A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSIO | $5.6M | 0 | 99 |
| A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | $5.2M | 1 | 467 |
| Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis | $5.2M | 0 | 396 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | $5.2M | 1 | 852 |
| A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD | $3.8M | 0 | 53 |
| A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED PARKINSON’S DISEASE | $3.8M | 0 | 50 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY PARKINSON'S DISEASE | $3.4M | 0 | 87 |
| A Phase 1 randomized, double-blind, placebo-controlled, 3-way crossover (Part A) and 2-arm parallel group (Part B) study to assess the pulmonary safety of staccato alprazolam in healthy study participants (Part A) and in study participants | $2.7M | 0 | 85 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY PARKINSONS DISEASE | $2.7M | 0 | 228 |
| Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized Myasthenia Gravis | $2.5M | 0 | 273 |
| A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD | $2.5M | 0 | 34 |
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY FOLLOWED BY AN OBSERVATIONAL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS. | $2.4M | 1 | 79 |
| AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS | $2.4M | 0 | 154 |
| A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH AN INITIAL TREATMENT PERIOD FOLLOWED BY A RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. | $2.4M | 0 | 68 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | $2.4M | 1 | 222 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIA | $2.3M | 0 | 54 |
| A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | $2.1M | 2 | 366 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSO | $2.1M | 0 | 59 |
| A Phase 1/2 Open-Label, MULTICENTER Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants with Advanced Solid Tumors | $2.0M | 0 | 36 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | $2.0M | 0 | 55 |
| A PHASE 3, RANDOMIZED, DOUBL-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS | $1.9M | 0 | 250 |
| An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizures | $1.7M | 0 | 232 |
| A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES | $1.6M | 0 | 235 |
| A RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS | $1.6M | 0 | 128 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | $1.6M | 1 | 146 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Randall Bateman, Md, MD | Neurology | Saint Louis, MO | $66,000 | $0 |
| Dr. Gil Wolfe, Md, MD | Neurology | Buffalo, NY | $64,438 | $0 |
| Pavel Klein, Md, MD | Neurology | Bethesda, MD | $63,473 | $0 |
| Prof. James Krueger, Md, Phd, MD, PHD | Dermatology | New York, NY | $62,627 | $0 |
| Jesus Pina-Garza, Md, MD | Neurology | Nashville, TN | $62,478 | $0 |
| Dr. Jacqueline French, Md, MD | Neurology | New York, NY | $62,441 | $0 |
| James Howard, Md, MD | Neurology | Chapel Hill, NC | $62,128 | $0 |
| Dr. Alexandra Kimball, Md Mph, MD MPH | Dermatology | Boston, MA | $58,963 | $0 |
| Christopher Ritchlin, Md, MD | Internal Medicine | Rochester, NY | $57,943 | $0 |
| Dr. Amit Garg, M.d, M.D | Dermatopathology | New Hyde Park, NY | $56,748 | $0 |
| Dr. Joseph Sirven, M.d, M.D | Neurology | Jacksonville, FL | $52,194 | $0 |
| Kenneth Gordon, M.d, M.D | Dermatology | Wauwatosa, WI | $51,823 | $0 |
| Joel Gelfand, Md, MD | Dermatology | Philadelphia, PA | $50,968 | $0 |
| Dr. Henry Kaminski, M.d, M.D | Neurology | Washington Dc, DC | $50,852 | $0 |
| Dr. Evan Rieder, M.d, M.D | Psychiatry | New York, NY | $49,050 | $0 |
| Unknown Provider | — | — | $48,485 | $0 |
| Dr. Angela Scheuerle, M.d, M.D | Clinical Genetics (M.D.) | Dallas, TX | $47,125 | $0 |
| Dr. Abul Abbas, Mbbs, MBBS | Anatomic Pathology | San Francisco, CA | $46,687 | $0 |
| Dr. David Stoll, M.d, M.D | Specialist | Beverly Hills, CA | $46,460 | $0 |
| Dr. David Kuter, Md Dphil, MD DPHIL | Internal Medicine | Boston, MA | $45,815 | $0 |
| David Fiorentino, Md, MD | Dermatology | Stanford, CA | $43,320 | $0 |
| Dr. Tuan Vu, Md, MD | Neurology | Tampa, FL | $41,902 | $0 |
| Dr. Carl Peck, M.d, M.D | Clinical Pharmacology | San Luis Obispo, CA | $41,845 | $0 |
| Dr. Jeffrey Noebels, Md, MD | Research | Houston, TX | $39,143 | $0 |
| Dr. Dinesh Khanna, M.d, M.D | Internal Medicine | Ann Arbor, MI | $38,760 | $0 |
About UCB SA
UCB SA has made $178.5M in payments to 558 healthcare providers, recorded across 16,078 transactions in the CMS Open Payments database. In 2024, the company paid $20.6M. The top product by payment volume is Cimzia ($6.1M).
Payments were distributed across 76 medical specialties. The top specialty by payment amount is Neurology ($2.3M to 160 doctors).
Payment categories include: Food & Beverage ($79,684), Consulting ($6.7M), Research ($170.3M), Travel & Lodging ($1.2M).
UCB SA is associated with 5 products in the CMS Open Payments database, including Rystiggo, Zilbrysq, and Evenity.